Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
- Registration Number
- NCT06717958
- Lead Sponsor
- Technische Universität Dresden
- Brief Summary
maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days
- Detailed Description
Determination of the efficacy of Ivosidenib to improve event-free survival when given as maintenance therapy following alloSCT.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 76
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Ivosidenib Ivosidenib 250 MG (milligram) -
- Primary Outcome Measures
Name Time Method event-free survival 24 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (12)
Universitätsklinikum Aachen
🇩🇪Aachen, Germany
Technische Universitaet Dresden, Medizinische Klinik und Poliklinik I
🇩🇪Dresden, Germany
Universitätsklinikum Essen
🇩🇪Essen, Germany
Martin-Luther-Universitaet Halle-Wittenberg
🇩🇪Halle, Germany
University Medical Center Hamburg-Eppendorf
🇩🇪Hamburg, Germany
Universitätsklinikum Jena
🇩🇪Jena, Germany
Universitätsklinikum Schleswig-Holstein
🇩🇪Kiel, Germany
Universität Leipzig
🇩🇪Leipzig, Germany
Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)
🇩🇪München, Germany
Universität Münster
🇩🇪Münster, Germany
Scroll for more (2 remaining)Universitätsklinikum Aachen🇩🇪Aachen, GermanyEdgar JostContact+49241800info@ukaachen.de